Variations in the Referral Pattern for Genetic Counseling of Patients with Early-Onset Breast Cancer: A Population-Based Study in Southern Sweden.
BRCA1
BRCA2
Breast cancer
Early-onset
Genetic counseling
Journal
Public health genomics
ISSN: 1662-8063
Titre abrégé: Public Health Genomics
Pays: Switzerland
ID NLM: 101474167
Informations de publication
Date de publication:
2020
2020
Historique:
received:
26
11
2019
accepted:
05
05
2020
pubmed:
9
7
2020
medline:
9
2
2021
entrez:
9
7
2020
Statut:
ppublish
Résumé
Swedish national breast cancer guidelines recommend that all women diagnosed with breast cancer (BC) at the age of 35 years or younger should be referred to their regional oncogenetic clinic for genetic counseling and testing, regardless of family history of cancer. The main objective of this study was to evaluate whether place of residence at BC diagnosis and treating hospital were associated with the fact that not all BC patients diagnosed at ≤35 years in the southern part of Sweden have attended genetic counseling and testing. Between 2000 and 2013, 279 women in the South Swedish Health Care Region were diagnosed with BC at ≤35 years. Information regarding place of residence at BC diagnosis, treating hospital, time of registration and first meeting at the Oncogenetic Clinic in Lund, and genetic testing was collected. With a follow-up period until August 2018, 64% were registered at the clinic (60% underwent genetic testing) and 36% were not. BC patients from 2 counties and from rural settings with a population of <10,000 inhabitants were significantly less likely to be registered at the clinic. Our results suggest that place of residence at BC diagnosis and treating hospital were associated with the probability of referral for genetic counseling and testing for women diagnosed with BC at ≤35 years in the South Swedish Health Care Region. We propose, as a generalizable finding, that further educational and outreach activities within the health care system and the community may be needed to ensure that all women diagnosed with early-onset BC receive proper genetic counseling.
Identifiants
pubmed: 32640451
pii: 000508684
doi: 10.1159/000508684
pmc: PMC7592930
doi:
Substances chimiques
BRCA1 Protein
0
BRCA2 Protein
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100-109Informations de copyright
© 2020 The Author(s) Published by S. Karger AG, Basel.
Références
Hum Genet. 2018 Oct;137(10):769-778
pubmed: 30328515
Breast. 2014 Jun;23(3):209-20
pubmed: 24767882
Breast. 2016 Apr;26:87-99
pubmed: 27017247
Acta Oncol. 2018 May;57(5):595-603
pubmed: 29164969
JAMA Oncol. 2016 Jun 1;2(6):730-6
pubmed: 26867710
PLoS One. 2017 May 25;12(5):e0177893
pubmed: 28542378
Clin Transl Oncol. 2015 Dec;17(12):956-61
pubmed: 26669313
Breast Cancer Res Treat. 2016 Jan;155(1):165-73
pubmed: 26706041
Mutat Res. 2017 Oct;774:33-45
pubmed: 29173497
J Community Genet. 2017 Apr;8(2):141-146
pubmed: 28299592
Cancer. 2011 Dec 1;117(23):5334-43
pubmed: 21792861
J Community Genet. 2011 Dec;2(4):233-47
pubmed: 22109876
Acta Oncol. 2009;48(1):86-92
pubmed: 18759137
Cancer Med. 2019 Mar;8(3):1306-1314
pubmed: 30734520
Am J Surg. 2009 Oct;198(4):538-43
pubmed: 19800464
J Community Genet. 2012 Oct;3(4):265-74
pubmed: 22426886
Eur J Cancer Care (Engl). 2010 May;19(3):369-76
pubmed: 19659662
J Exp Clin Cancer Res. 2008 Nov 24;27:75
pubmed: 19025627
Acta Oncol. 2004;43(7):637-49
pubmed: 15545184
Clin Adv Hematol Oncol. 2018 May;16(5):330-332
pubmed: 29851928
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Int J Gynecol Cancer. 2013 Mar;23(3):431-6
pubmed: 23354368